search
Back to results

Effect Dietary Fructose on Fructose Kinetics in Type 2 Diabetes (ERIE)

Primary Purpose

Type 2 Diabetes

Status
Recruiting
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Type 2 Diabetes

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: 40 T2D patients (20 Caucasian and 20 SAS) 40-70 years old Male-female BMI 25-35 kg/m2 Stable anti diabetic drugs for 3 months (metformin is obligatory) Stable medication use past 3 months Able to give informed consent Exclusion Criteria: - Proton-pump inhibitor usage (known to effect gut microbiota) GLP1, SGLT2i or insulin use (known to effect gut microbiota) Antibiotic for the past 3 months (known to effect gut microbiota) Probiotic or symbiotic usage (known to effect gut microbiota) Pregnant women Chronic illness (including a known history of heart failure, renal failure (eGFR <30 ml/min), pulmonary disease, gastrointestinal disorders, or hematologic diseases), or other inflammatory diseases Active infection Previous intestinal (e.g., bowel resection/reconstruction) surgery Smoking (due to its influence on gut microbiome) Vegetarian diet (since they have different microbiota) >6 alcohol units per day or >14 alcohol units per week Active malignancy HbA1c >9% (75mmol/mol)

Sites / Locations

  • Amsterdam UMC location AMCRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

high fructose in caucasian dutch type 2 diabetes subjects

low fructose in caucasian dutch type 2 diabetes subjects

high fructose in surinamese asian type 2 diabetes

low fructose in surinamese asian type 2 diabetes

Arm Description

high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.

low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.

high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.

low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.

Outcomes

Primary Outcome Measures

fructose on glucose metabolism
to correlate changes in oral fructose handling (measured by a fructose challenge test (AUC) with 13C6-labeled fructose in relation to metabolic effects on HOMA-IR and continuous glucose monitoring (Freestyle libre MAGE) at baseline and after 4 weeks of dietary intervention.

Secondary Outcome Measures

changes in microbiota composition
correlate with changes in oral/fecal microbiota composition (diversity and strain)
changes in (postprandial )plasma metabolites
effects of the diet on body composition (measured via bio impedance analysis). We will also collects 24h feces and urine before each study visit to determine correlate with changes in (postprandial) untargeted plasma metabolites including endogenous ethanol

Full Information

First Posted
January 8, 2023
Last Updated
January 29, 2023
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
search

1. Study Identification

Unique Protocol Identification Number
NCT05717608
Brief Title
Effect Dietary Fructose on Fructose Kinetics in Type 2 Diabetes
Acronym
ERIE
Official Title
Effect Dietary Fructose on Fructose Kinetics in Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 5, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
April 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Determine the kinetics of fructose metabolism and its role as a metabolic substrate following a high (100gr/day) vs low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) in type 2 diabetic subjects of SAS or Caucasian ethnicity.
Detailed Description
The prevalence and accompanying morbidity and mortality of obesity and type 2 diabetes (T2D) is increasing on a global scale. Unfortunately the underlying (patho)physiological mechanisms are only partially understood. A key step in the development of negative health effects of metabolic disease might be via dietary fructose metabolism and its accompanying aberrant metabolite production, in which our gut microbiota plays a crucial role. By bypassing the normal glucose metabolism pathway, fructose plays a role in the development of metabolic disease such as diabetes en fatty liver disease. The mechanism of this effect is unclear and possibly plays in the observation of ethnic specific metabolic risk factors. That is, subjects of different ethnicties (for instance South-Asian Surinamese (SAS)) have a higher risk and worse trajectory of metabolic diseases than Caucasians. Since gut microbiota is altered between these two ethnicities, we hypothesize that aberreant fructose catabolism in patients of SAS descent results in production of specific (gut microbiota derived) metabolites such as ethanol. In this study, fructose metabolism will thus be studied in patients of SAS and Caucasian Dutch descent. To this end the investigators will examine (13C stable isotope based) fructose fluxes before and after randomizing subjects into a four-week high- or low fructose diet. This study aims to elucidate the physiological and microbial catabolism of fructose and possible differences between these two ethnicities.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
high versus low fructose diet for 4 weeks in either caucasian or surinamese asian type 2 diabetes patients
Masking
ParticipantInvestigator
Masking Description
supplementation with either fructose or dextrose
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
high fructose in caucasian dutch type 2 diabetes subjects
Arm Type
Active Comparator
Arm Description
high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
Arm Title
low fructose in caucasian dutch type 2 diabetes subjects
Arm Type
Placebo Comparator
Arm Description
low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of Caucasian ethnicity.
Arm Title
high fructose in surinamese asian type 2 diabetes
Arm Type
Active Comparator
Arm Description
high (100gr/day) fructose diet for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
Arm Title
low fructose in surinamese asian type 2 diabetes
Arm Type
Placebo Comparator
Arm Description
low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks in type 2 diabetic subjects of SAS ethnicity.
Intervention Type
Other
Intervention Name(s)
high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Intervention Description
oral ingestion of food supplement for 4 weeks
Primary Outcome Measure Information:
Title
fructose on glucose metabolism
Description
to correlate changes in oral fructose handling (measured by a fructose challenge test (AUC) with 13C6-labeled fructose in relation to metabolic effects on HOMA-IR and continuous glucose monitoring (Freestyle libre MAGE) at baseline and after 4 weeks of dietary intervention.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
changes in microbiota composition
Description
correlate with changes in oral/fecal microbiota composition (diversity and strain)
Time Frame
4 weeks
Title
changes in (postprandial )plasma metabolites
Description
effects of the diet on body composition (measured via bio impedance analysis). We will also collects 24h feces and urine before each study visit to determine correlate with changes in (postprandial) untargeted plasma metabolites including endogenous ethanol
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 40 T2D patients (20 Caucasian and 20 SAS) 40-70 years old Male-female BMI 25-35 kg/m2 Stable anti diabetic drugs for 3 months (metformin is obligatory) Stable medication use past 3 months Able to give informed consent Exclusion Criteria: - Proton-pump inhibitor usage (known to effect gut microbiota) GLP1, SGLT2i or insulin use (known to effect gut microbiota) Antibiotic for the past 3 months (known to effect gut microbiota) Probiotic or symbiotic usage (known to effect gut microbiota) Pregnant women Chronic illness (including a known history of heart failure, renal failure (eGFR <30 ml/min), pulmonary disease, gastrointestinal disorders, or hematologic diseases), or other inflammatory diseases Active infection Previous intestinal (e.g., bowel resection/reconstruction) surgery Smoking (due to its influence on gut microbiome) Vegetarian diet (since they have different microbiota) >6 alcohol units per day or >14 alcohol units per week Active malignancy HbA1c >9% (75mmol/mol)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
cengiz callender, MD
Phone
0031 20 5669111
Email
c.callender@amsterdamumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
max nieuwdorp, MD PhD
Phone
0031 20 5669111
Email
m.nieuwdorp@amsterdamumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
max nieuwdorp
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amsterdam UMC location AMC
City
Amsterdam
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
max nieuwdorp, MD PhD
Phone
0031 20 5669111
Email
m.nieuwdorp@amsterdamumc.nl

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
not allowed due to dutch GDPR regulations

Learn more about this trial

Effect Dietary Fructose on Fructose Kinetics in Type 2 Diabetes

We'll reach out to this number within 24 hrs